98%
921
2 minutes
20
Background And Purpose: There is limited high-level evidence to guide locally advanced pancreas cancer (LAPC) management. Recent work shows that surgeons' preferences in LAPC management vary broadly. We sought to examine whether surgeon volume was associated with attitudes regarding LAPC management.
Methods: An electronic survey was distributed by email to an international cohort of pancreas surgeons to evaluate practice patterns regarding LAPC management. Clinical vignette-based questions evaluated surgeons' attitudes regarding patient eligibility and the proclivity to offer exploration. Surgeons were classified into "low-" or "high-volume" categories according to thresholds of self-reported annual pancreatectomy volume. Surgeon's attitudes regarding LAPC management and inclination to consider exploration were compared across annual volume categories.
Results: A total of 153 eligible responses were received from 4 continents, for an estimated response rate of 10.6%. Median duration of practice was 12 years (IQR 6-20). Most respondents reported >25 cases/year (89, 58.2%), of which 34 (22.2%) reported >50. Compared to surgeons with <25 cases/year, surgeons with >25 cases/year practiced longer (median 15 vs. 7.5 years, P<0.001) and were more likely to "always" recommend neoadjuvant chemotherapy (83.2% vs. 56.3%, P=0.001). Surgeons performing >50 cases/year were more likely to offer arterial resection (70.6% vs. 43.7%, P=0.006). The willingness to offer (or defer) exploration did not differ across any categories of surgeons' annual case volume.
Conclusions: In an international survey of pancreas surgeons, the proclivity to consider exploration for LAPC was not associated with multiple categories of surgeon volume. Better evidence is needed to define the optimal management approach to LAPC.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11605-021-05034-w | DOI Listing |
Adv Surg
September 2025
Division of Surgical Oncology, Hiram C Polk Department of Surgery, University of Louisville School of Medicine, 315 E. Broadway - M10 - Room#311, Louisville, KY 40202, USA.
Irreversible electroporation (IRE) has proven itself to be a viable surgical intervention for patients with borderline resectable pancreatic cancer and locally-advanced pancreatic cancer (LAPC). IRE has demonstrated encouraging survival and response outcomes when combined with induction chemotherapy versus patient populations that receive chemotherapy and/or chemo-radiation therapy alone. The optimal management of patients with LAPC is evolving quickly with the advent of improved IRE implementation.
View Article and Find Full Text PDFCureus
June 2025
Orthopaedic Surgery, Nagoya Nishi Hospital, Nagoya, JPN.
The incidence and mortality rates of pancreatic cancer have been increasing. Due to the high likelihood of metastasis and vascular invasion, most pancreatic cancer cases are inoperable at the time of diagnosis. Carbon-ion radiotherapy (CIRT) has recently been introduced as a treatment option for locally advanced pancreatic cancer (LAPC).
View Article and Find Full Text PDFBr J Surg
July 2025
Amsterdam UMC, Location University of Amsterdam, Department of Surgery, Amsterdam, The Netherlands.
Cancers (Basel)
June 2025
Department of Gastrointestinal Oncology, University College London Hospitals NHS Foundation Trust, London NW1 2BU, UK.
We reviewed outcomes of short and long-term chemotherapy with or without breaks in pancreatic ductal adenocarcinoma (PDAC) patients. PDAC patients receiving ≥3 chemotherapy cycles between 2019 and 2024 at three institutions were included. Progression-free survival after first-line chemotherapy (PFS1), overall survival (OS) and best overall response (BOR) to chemotherapy were assessed using the Wilcoxon test, Kaplan-Meier test, and univariate and multivariate Cox regression models.
View Article and Find Full Text PDFBr J Cancer
July 2025
Division of Surgical Oncology, Department of Surgery, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.
Background: It remains unclear whether there is a difference in overall survival (OS) benefit between (m)FOLFIRINOX and gemcitabine-nab-paclitaxel as preoperative regimens for localised pancreatic adenocarcinoma. This study aimed to investigate the outcome of patients with resected localised pancreatic adenocarcinoma following (m)FOLFIRINOX versus gemcitabine-nab-paclitaxel.
Methods: International multicentre retrospective study (16 centres, 8 countries, 3 continents), including consecutive patients after pancreatic resection for localised pancreatic adenocarcinoma following 2-6 months preoperative (m)FOLFIRINOX or gemcitabine-nab-paclitaxel (2010-2018).